MedTrace Logo

A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

NCT01435902 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-06-23

No results posted yet for this study

Summary

The primary objective of this study is to demonstrate that the combination of inhaled fluticasone furoate/vilanterol (100 mcg/25 mcg) once daily provides superior protection throughout the day against bronchoconstriction induced by exercise compared with fluticasone propionate 250 mcg twice daily in adolescent and adult subjects aged 12 to 50 diagnosed with persistent asthma.

Conditions

Interventions

DRUG

Fluticasone Furoate/Vilanterol Inhalation Powder

Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks

DRUG

Fluticasone Propionate Inhalation Powder

Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-08-31
Completion
2012-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01435902 on ClinicalTrials.gov